North America Stem Cell Assay Market Report and Forecast 2025-2034
Description
The North America stem cell assay market size was valued at USD 7.10 Billion in 2024, driven by the increased investment in stem cell research in the region. The market is expected to grow at a CAGR of 10.08% during the forecast period of 2025-2034, with the values likely to rise from USD 18.55 Billion by 2034.
Stem cell assay is a laboratory technique that helps to evaluate the behavior and function of stem cells. These assays find their applications in studying stem cell biology and assessing their potential therapeutic use. The rising cases of various chronic diseases in the region such as cancer are expected to directly impact the demand for novel treatment options, thereby driving the North America stem cell assay market growth. For instance, according to the American Cancer Society, it is estimated that 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States in 2024. Further, increased applications of stem cell assays in drug discovery and regenerative medicine are likely to augment the market size in the forecast period.
In North America, the rising impetus for stem cell research is resulting in advancements in stem cell assay methods and therapies. The development of innovative methods is expected to boost North America stem cell assay market demand as they can assist healthcare professionals in personalizing chemotherapy selection for cancer patients and in identifying the most effective therapy for each patient. In May 2023 , a study published in Cell Reports Medicine revealed that a cancer stem cell assay called ChemoID can accurately predict clinical outcomes in response to chemotherapy, improving the survival of patients with recurrent glioblastoma. In the randomized trial, the group guided by the ChemoID assay showed a median survival of 12.5 months, compared to 9 months in the physician-choice group. These findings offer a promising approach to providing more affordable treatment for patients with recurrent glioblastoma in lower socioeconomic groups in the United States.
North America stem cell assay market share is likely to be impacted by increased merger and acquisition initiatives among the key market players. In April 2023, a United States-based company specializing in biospecimen, biomarker, and proteogenomics Discovery Life Sciences acquired ReachBio Research Labs, a life sciences company based in Seattle known for their cell-based assays, drug screening services, and predictive hematotoxicity. The acquisition will enable Discovery Life Science to expand its offerings in drug discovery and preclinical development by leveraging ReachBio’s expertise in primary cell biology, particularly blood and bone marrow stem cell assays. The growing number of such strategic partnerships is anticipated to accelerate market growth in the coming years.
Other factors that fuel the market growth are the advancements in stem cell technologies resulting in enhanced efficiency and throughput of stem cell assays, increased healthcare expenditure, and rising funding for stem cell-based research. Further, the growing demand for personalized medicine and precision therapies will accelerate the market growth in the region.
North America Stem Cell Assay Market Segmentation
North America Stem Cell Assay Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Breakup by Product & Service
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Stem cell assay is a laboratory technique that helps to evaluate the behavior and function of stem cells. These assays find their applications in studying stem cell biology and assessing their potential therapeutic use. The rising cases of various chronic diseases in the region such as cancer are expected to directly impact the demand for novel treatment options, thereby driving the North America stem cell assay market growth. For instance, according to the American Cancer Society, it is estimated that 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States in 2024. Further, increased applications of stem cell assays in drug discovery and regenerative medicine are likely to augment the market size in the forecast period.
In North America, the rising impetus for stem cell research is resulting in advancements in stem cell assay methods and therapies. The development of innovative methods is expected to boost North America stem cell assay market demand as they can assist healthcare professionals in personalizing chemotherapy selection for cancer patients and in identifying the most effective therapy for each patient. In May 2023 , a study published in Cell Reports Medicine revealed that a cancer stem cell assay called ChemoID can accurately predict clinical outcomes in response to chemotherapy, improving the survival of patients with recurrent glioblastoma. In the randomized trial, the group guided by the ChemoID assay showed a median survival of 12.5 months, compared to 9 months in the physician-choice group. These findings offer a promising approach to providing more affordable treatment for patients with recurrent glioblastoma in lower socioeconomic groups in the United States.
North America stem cell assay market share is likely to be impacted by increased merger and acquisition initiatives among the key market players. In April 2023, a United States-based company specializing in biospecimen, biomarker, and proteogenomics Discovery Life Sciences acquired ReachBio Research Labs, a life sciences company based in Seattle known for their cell-based assays, drug screening services, and predictive hematotoxicity. The acquisition will enable Discovery Life Science to expand its offerings in drug discovery and preclinical development by leveraging ReachBio’s expertise in primary cell biology, particularly blood and bone marrow stem cell assays. The growing number of such strategic partnerships is anticipated to accelerate market growth in the coming years.
Other factors that fuel the market growth are the advancements in stem cell technologies resulting in enhanced efficiency and throughput of stem cell assays, increased healthcare expenditure, and rising funding for stem cell-based research. Further, the growing demand for personalized medicine and precision therapies will accelerate the market growth in the region.
North America Stem Cell Assay Market Segmentation
North America Stem Cell Assay Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Breakup by Product & Service
- Flow Cytometers
- Cell Imaging & Analysis Systems
- Microelectrode Arrays
- Automated Cell Counters
- Kits
- Adult Stem Cells
- Human Embryonic Stem Cells
- Pluripotent
- Viability /Cytotoxicity Assays
- Isolation & Purification Assays
- Cell Identification Assays
- Proliferation Assays
- Differentiation Assays
- Function Assays
- Apoptosis Assays
- Others
- Allogeneic Stem Cell Therapy
- Autologic Stem Cell Therapy
- Syngeneic Stem Cell Therapy
- Regenerative Medicine &Therapy Development
- Drug Discovery & Development
- Clinical Research
- Others
- Biopharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
- United States of America
- Canada
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific
- Perkinelmer
- Stemcell Technologies
- Merck
- Bio-Rad Laboratories
- Agilent Technologies
- Promega
- Bio-Techne
- Cell Biolabs
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 North America Stem Cell Assay Market Overview
- 3.1 North America Stem Cell Assay Market Historical Value (2018-2024)
- 3.2 North America Stem Cell Assay Market Forecast Value (2025-2034)
- 4 North America Stem Cell Assay Market Landscape*
- 4.1 North America Osmometers: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 North America Osmometers: Product Landscape
- 4.2.1 Analysis by Product
- 4.2.2 Analysis by Cell Type
- 4.2.3 Analysis by Treatment
- 5 North America Stem Cell Assay Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 North America Stem Cell Assay Market Segmentation (218-2034)
- 6.1 North America Stem Cell Assay Market (2018-2034) by Product & Service
- 6.1.1 Market Overview
- 6.1.2 Flow Cytometers
- 6.1.3 Cell Imaging & Analysis Systems
- 6.1.4 Microelectrode Arrays
- 6.1.5 Automated Cell Counters
- 6.1.6 Kits
- 6.2 North America Stem Cell Assay Market (2018-2034) by Cell Type
- 6.2.1 Market Overview
- 6.2.2 Adult Stem Cells
- 6.2.3 Human Embryonic Stem Cells
- 6.2.4 Pluripotent
- 6.3 North America Stem Cell Assay Market (2018-2034) by Type
- 6.3.1 Market Overview
- 6.3.2 Viability /Cytotoxicity Assays
- 6.3.3 Isolation & Purification Assays
- 6.3.4 Cell Identification Assays
- 6.3.5 Proliferation Assays
- 6.3.6 Differentiation Assays
- 6.3.7 Function Assays
- 6.3.8 Apoptosis Assays
- 6.3.9 Others
- 6.4 North America Stem Cell Assay Market (2018-2034) by Treatment
- 6.4.1 Market Overview
- 6.4.2 Allogeneic Stem Cell Therapy
- 6.4.3 Autologic Stem Cell Therapy
- 6.4.4 Syngeneic Stem Cell Therapy
- 6.5 North America Stem Cell Assay Market (2018-2034) by Application
- 6.5.1 Market Overview
- 6.5.2 Regenerative Medicine &Therapy Development
- 6.5.3 Drug Discovery & Development
- 6.5.4 Clinical Research
- 6.5.5 Others
- 6.6 North America Stem Cell Assay Market (2018-2034) by End User
- 6.6.1 Market Overview
- 6.6.2 Biopharmaceutical & Biotechnology Companies
- 6.6.3 Academic & Research Institutes
- 6.6.4 Others
- 6.7 North America Stem Cell Assay Market (2018-2034) by Countries
- 6.7.1 Market Overview
- 6.7.2 United States of America
- 6.7.3 Canada
- 7 United States of America of Stem Cell Assay Market (218-2034)
- 7.1 United State of America Stem Cell Assay Market (2018-2034) by Product & Service
- 7.1.1 Market Overview
- 7.1.2 Flow Cytometers
- 7.1.3 Cell Imaging & Analysis Systems
- 7.1.4 Microelectrode Arrays
- 7.1.5 Automated Cell Counters
- 7.1.6 Kits
- 7.2 United States of America Stem Cell Assay Market (2018-2034) by Cell Type
- 7.2.1 Market Overview
- 7.2.2 Adult Stem Cells
- 7.2.3 Human Embryonic Stem Cells
- 7.2.4 Pluripotent
- 7.3 United States of America Stem Cell Assay Market (2018-2034) by Type
- 7.3.1 Market Overview
- 7.3.2 Viability /Cytotoxicity Assays
- 7.3.3 Isolation & Purification Assays
- 7.3.4 Cell Identification Assays
- 7.3.5 Proliferation Assays
- 7.3.6 Differentiation Assays
- 7.3.7 Function Assays
- 7.3.8 Apoptosis Assays
- 7.3.9 Others
- 7.4 United State of America Stem Cell Assay Market (2018-2034) by Treatment
- 7.4.1 Market Overview
- 7.4.2 Allogeneic Stem Cell Therapy
- 7.4.3 Autologic Stem Cell Therapy
- 7.4.4 Syngeneic Stem Cell Therapy
- 7.5 United State of America Stem Cell Assay Market (2018-2034) by End User
- 7.5.1 Market Overview
- 7.5.2 Biopharmaceutical & Biotechnology Companies
- 7.5.3 Academic & Research Institutes
- 7.5.4 Others
- 7.6 United State of America Stem Cell Assay Market (2018-2034) by Application
- 7.6.1 Market Overview
- 7.6.2 Regenerative Medicine &Therapy Development
- 7.6.3 Drug Discovery & Development
- 7.6.4 Clinical Research
- 7.6.5 Others
- 8 Canada Stem Cell Assay Market (218-2034)
- 8.1 Canada Stem Cell Assay Market (2018-2034) by Product & Service
- 8.1.1 Market Overview
- 8.1.2 Flow Cytometers
- 8.1.3 Cell Imaging & Analysis Systems
- 8.1.4 Microelectrode Arrays
- 8.1.5 Automated Cell Counters
- 8.1.6 Kits
- 8.2 Canada Stem Cell Assay Market (2018-2034) by Cell Type
- 8.2.1 Market Overview
- 8.2.2 Adult Stem Cells
- 8.2.3 Human Embryonic Stem Cells
- 8.2.4 Pluripotent
- 8.3 Canada Stem Cell Assay Market (2018-2034) by Type
- 8.3.1 Market Overview
- 8.3.2 Viability /Cytotoxicity Assays
- 8.3.3 Isolation & Purification Assays
- 8.3.4 Cell Identification Assays
- 8.3.5 Proliferation Assays
- 8.3.6 Differentiation Assays
- 8.3.7 Function Assays
- 8.3.8 Apoptosis Assays
- 8.3.9 Others
- 8.4 Canada Stem Cell Assay Market (2018-2034) by Treatment
- 8.4.1 Market Overview
- 8.4.2 Allogeneic Stem Cell Therapy
- 8.4.3 Autologic Stem Cell Therapy
- 8.4.4 Syngeneic Stem Cell Therapy
- 8.5 Canada Stem Cell Assay Market (2018-2034) by End User
- 8.5.1 Market Overview
- 8.5.2 Biopharmaceutical & Biotechnology Companies
- 8.5.3 Academic & Research Institutes
- 8.5.4 Others
- 8.6 Canada Stem Cell Assay Market (2018-2034) by Application
- 8.6.1 Market Overview
- 8.6.2 Regenerative Medicine &Therapy Development
- 8.6.3 Drug Discovery & Development
- 8.6.4 Clinical Research
- 8.6.5 Others
- 9 Regulatory Framework
- 10 Patent Analysis
- 10.1 Analysis by Type of Patent
- 10.2 Analysis by Publication year
- 10.3 Analysis by Issuing Authority
- 10.4 Analysis by Patent Age
- 10.5 Analysis by CPC Analysis
- 10.6 Analysis by Patent Valuation
- 10.7 Analysis by Key Players
- 11 Funding and Investment Analysis
- 11.1 Analysis by Funding Instances
- 11.2 Analysis by Type of Funding
- 11.3 Analysis by Funding Amount
- 11.4 Analysis by Leading Players
- 11.5 Analysis by Leading Investors
- 11.6 Analysis by Geography
- 12 Partnership and Collaborations Analysis
- 12.1 Analysis by Partnership Instances
- 12.2 Analysis by Type of Partnership
- 12.3 Analysis by Leading Players
- 12.4 Analysis by Geography
- 13 Supplier Landscape
- 13.1 Market Share by Top 5 Companies
- 13.2 Thermo Fisher Scientific
- 13.2.1 Financial Analysis
- 13.2.2 Product Portfolio
- 13.2.3 Demographic Reach and Achievements
- 13.2.4 Mergers and Acquisitions
- 13.2.5 Certifications
- 13.3 Perkinelmer
- 13.3.1 Financial Analysis
- 13.3.2 Product Portfolio
- 13.3.3 Demographic Reach and Achievements
- 13.3.4 Mergers and Acquisitions
- 13.3.5 Certifications
- 13.4 Stemcell Technologies
- 13.4.1 Financial Analysis
- 13.4.2 Product Portfolio
- 13.4.3 Demographic Reach and Achievements
- 13.4.4 Mergers and Acquisitions
- 13.4.5 Certifications
- 13.5 Merck
- 13.5.1 Financial Analysis
- 13.5.2 Product Portfolio
- 13.5.3 Demographic Reach and Achievements
- 13.5.4 Mergers and Acquisitions
- 13.5.5 Certifications
- 13.6 Bio-Rad Laboratories
- 13.6.1 Financial Analysis
- 13.6.2 Product Portfolio
- 13.6.3 Demographic Reach and Achievements
- 13.6.4 Mergers and Acquisitions
- 13.6.5 Certifications
- 13.7 Agilent Technologies
- 13.7.1 Financial Analysis
- 13.7.2 Product Portfolio
- 13.7.3 Demographic Reach and Achievements
- 13.7.4 Mergers and Acquisitions
- 13.7.5 Certifications
- 13.8 Promega
- 13.8.1 Financial Analysis
- 13.8.2 Product Portfolio
- 13.8.3 Demographic Reach and Achievements
- 13.8.4 Mergers and Acquisitions
- 13.8.5 Certifications
- 13.9 Bio-Techne
- 13.9.1 Financial Analysis
- 13.9.2 Product Portfolio
- 13.9.3 Demographic Reach and Achievements
- 13.9.4 Mergers and Acquisitions
- 13.9.5 Certifications
- 13.10 Cell Biolabs
- 13.10.1 Financial Analysis
- 13.10.2 Product Portfolio
- 13.10.3 Demographic Reach and Achievements
- 13.10.4 Mergers and Acquisitions
- 13.10.5 Certifications
- 14 United States of America Cannula Market – Distribution Model (Additional Insight)
- 14.1 Overview
- 14.2 Potential Distributors
- 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
- 16.1 Very Small Companies
- 16.2 Small Companies
- 16.3 Mid-Sized Companies
- 16.4 Large Companies
- 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
- 17.1 Government Funded
- 17.2 Private Insurance
- 17.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
